Use of &Dgr;5-androstene-3&bgr;ol-7,17-dione in the treatment of lupus erythematosus
US6593316B2 · kind B2 · utility
1Cited by
5References
20Claims
0Family size
Inventors
Key dates
| Filing date | Mar 22, 2002 |
| Grant date | Jul 15, 2003 |
| Priority date | — |
| Expiry date | Mar 22, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Lupus erythematosus can be treated by administering therapeutic amounts of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and metabolizable precursors thereof, such as &Dgr;5-androstene-3&bgr;-acetoxy-7,17-dione, which are readily metabolized in vivo to &Dgr;5-androstene-3&bgr;-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.